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ABSTRACT
We evaluated the occurrence of severe infections in 192 consecutive adult recipients of volunteer unrelated
donor allogeneic hematopoietic stem cell transplants, with a detailed analysis of severe infections after receipt
of cord blood transplants (CBTs; n  48) or bone marrow transplants (BMTs)/peripheral blood stem cell
transplants (PBSCTs; n  144). At a 3-year median follow-up, CBT recipients had a higher risk of developing
any severe infection (85% versus 69% in BMT/PBSCT recipients, P < .01). CBT recipients had a higher
incidence of severe bacterial infections before day 100, but at 3 years the risks of these and other infections
were similar in the CBT and BMT/PBSCT groups. In addition, the 100-day and 3-year incidences of
infection-related mortality (IRM) did not differ between groups (P  .2 and .5, respectively). In multivariate
analysis, the most significant risk factor for IRM in all 192 patients was monocytopenia (.2  109/L). In CBT
recipients, only neutropenia (.2  109/L) on day 30 and low nucleated cell dose infusion (<2  107/kg)
showed a trend for increased IRM (P .05 in both cases). Stem cell source had no effect on day100 or 3-year
nonrelapse mortality (NRM), cytomegalovirus infection, cytomegalovirus disease (7% versus 6%), or overall
survival (36% versus 39%, respectively). The number of mismatches in HLA (A, B, and DRB1) had no effect
on any outcome in CBT recipients. In contrast, in the BMT/PBSCT group, the presence of any mismatch by
low or high-resolution HLA typing (A, B, C, and DRB1) increased NRM and decreased overall survival (P <
.01). IRM was the primary or secondary cause of death in 61% and 59% of CBT and BMT/PBSCT recipients
who died, respectively. Our results confirm the relevance of severe infectious complications as source of severe
morbidity and NRM after volunteer unrelated donor hematopoietic stem cell transplantation in adults, but
suggest that CBT recipients have a similar risk of dying from an infection if an accurate selection of a cord
blood unit is done.
© 2006 American Society for Blood and Marrow Transplantation
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Infections after Unrelated Allogeneic Transplantation in Adults 735NTRODUCTION
Serious infections are common problems after vol-
nteer unrelated donor (VUD) hematopoietic stem
ell transplantation (HSCT) and account for substan-
ial morbidity and mortality, especially in adults [1-8].
onrelapse mortality (NRM) due to infections has an
ncidence as high as 45% to 60% only in the ﬁrst year
fter HSCT [5,9,10,11]. Until recently, VUD HSCT
sed bone marrow transplants (BMTs) or peripheral
lood stem cell transplants (PBSCTs). In recent years,
owever, umbilical cord blood transplantation (CBT)
as been considered a valid alternative to BMT and
BSCT, and recent retrospective studies have sug-
ested that CBT in adults has similar outcomes as
MT from VUD, provided a high stem cell dose is
nfused [12-14].
However, severe infections may be more common
fter CBT than after BMT/PBSCT, in large part
ttributable to the slower hematopoietic and immune
econstitutions after CBT [12,13,15]. A recent retro-
pective study in children has shown that the risk of
evere infections after pediatric CBT is comparable to
hat of non–T-cell–depleted BMT and lower than
hat of T-cell–depleted BMT [16]. Similar studies are
carce in adults and have been reported with a short
ollow-up [11-14,17].
For this purpose we compared in detail the occur-
ence of severe infections after VUD transplantation
ith BMT or PBSCT with recipients of a CBT pro-
ocol in 192 adults, with special emphasis on infec-
ion-related mortality (IRM).
ETHODS
atient Selection
The present study was done by members of the
nfectious and Non-infectious Subcommittee of the
panish Group for Hematopoietic Transplantation
GETH). GETH member centers that perform 10
UD allogeneic HSCTs per year were invited to
articipate in this study. To reﬂect the reality seen in
linical practice and have 1-year follow-up for all
atients, centers had to complete an extensive case-
eport form for all consecutive patients who were15
ears old and received a VUD transplant with any
ource of stem cells between January 1997 and March
004. Seven centers agreed to participate, and the ﬁnal
atabase was closed in June 2005.
In accord with local, European, and international
egislation, all patients signed an informed consent be-
ore transplantation, which included authorization for
he reporting and use of their data (assuring conﬁdenti-
lity) for current or future studies. Speciﬁc transplanta-
ion protocols also had local and national authorization
ith institutional review board approval. fPatient characteristics and noninfectious transplan-
ation outcomes are presented in detail in Table 1. As
xpected, patients’ characteristics differed in various
aseline variables between stem cell transplantation
roups, as described in recent registry studies [12-14].
ransplantation Procedure and Supportive Care
Before hematopoietic engraftment, all patients were
solated in single rooms with high efﬁciency particulate
ir ﬁltration (n  150) or laminar airﬂow (n  42). All
atients received systemic antibiotic prophylaxis, starting
efore transplantation, which consisted of a ﬂuoroquin-
lone in 86% of cases. In addition, during neutropenia
ntiviral and antifungal prophylaxes consisted of acyclo-
ir and ﬂuconazole in 90% of patients.
High-dose acyclovir from days 4 to 30 was
sed as cytomegalovirus (CMV) prophylaxis immedi-
tely after HSCT in 46 patients (24%). Seven patients
3.5%) continued prophylaxis with ganciclovir or fos-
arnet even after engraftment and until 100 day after
SCT. In all other patients, preemptive therapy with
he latter 2 drugs was used. Both strategies were used
n similar proportions in CBT and BMT/PBSCT re-
ipients (pre-emptive therapy was used in 70% and
1% transplant groups, respectively). Monitoring of
MV infection was done at least weekly with detec-
ion of pp65 antigenemia in peripheral blood after
ngraftment in all cases, and qualitative or quantitative
olymerase chain reaction for CMV DNA was also
sed in 20% of patients (all after 2001). In a similar
anner, serum galactomannan was used routinely
nly since 2002, so results of polymerase chain reac-
ion–based diagnosis of CMV infection and galacto-
annan antigenemia for the diagnosis of invasive as-
ergillosis (IA) were not analyzed in this study because
heir inclusion could lead to a bias showing a falsely
igher number of CMV infections and probable IA in
he latter years.
After engraftment, 125 patients (73% of evaluable
atients on day 30) received cotrimoxazole for pro-
hylaxis against Pneumocystis jiroveci and toxoplasmo-
is. One hundred eleven patients (58%) received in-
ravenous immunoglobulin until day 100. There
ere no differences in supportive care procedures be-
ween transplantation groups (data not shown).
efinitions
As deﬁned in most studies, severe infections in-
luded those potentially associated with death or se-
ere clinical compromise, which is described in detail
elow. Other infections not requiring therapy or those
equiring only oral antibiotics on an outpatient basis
ere excluded from this study.
A pre-established homogeneous set of deﬁni-
ions was used by all participating centers, which
ollowed the proposed guidelines from the Infec-
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R. Parody et al.736able 1. Patient Characteristics and Main Transplantation Outcomes (n  192)
Transplant-Related Characteristics
CBT
(n  48)
BMT
(n  120)
PBSCT
(n  24) P
edian age, range 31 (16-47) 30 (16-59) 37 (16-54) .06
>35, y 18 (38) 38 (32) 14 (58) .05
ale 30 (62) 64 (54) 16 (67)
ex mismatched 22 (52) 48 (40) 11 (46)
Female donor/male recipient 13 (27) 20 (17) 7 (29)
nderlying disease
AL/MDS 29 (60) 60 (50) 16 (67)
CML 19 (40) 46 (38) 7 (29)
Lymphoid malignancies — 14 (12) 1 (4)
tatus at transplant*
Early 24 (50) 72 (60.5) 12 (50)
Not early 24 (50) 48 (40) 12 (50)
econd transplant 9 (19) 28 (23) 5 (20.9)
tatus of CMV serology
Recipient positive (high risk) 36 (75) 87 (73) 22 (92)
Recipient negative (intermediate and low risk) 12 (25) 32 (27) 2 (8)
eriod of transplantation
1997-2000 23 (48) 68 (57) 7 (29)
2001-2004 25 (52) 52 (43) 17 (71)
evel HLA testing available
Class I HLA (A, B, C) by PCR-HR 1 78 (65) 19 (79) <.001 for BM/PBSCT vs CBT
Class I HLA (A, B) by LR 45 (94) 42 (35) 5
Class II HLA (DRB1  DQB1) by PCR-HR 48 (100) 120 (100) 24 (100)
umber of known mismatches, if considering A
and B by LR and DRB1 by HR
6/6 match 5 (11) 110 (92) 20 (83) <.001 for BM/PBSCT vs CBT,
when comparing 6/6 match w
any mismatch
7/8 match NA 18/74 (24) 5/19 (26)
8/8 match NA 56/74 (76) 14/19 (74)
5/6 match 25 (52) 7 (6) 3 (13)
>1 mismatch 18 (38) 3 (3) 1 (4)
igh stem cell doses (see Definitions for details) 25 (52) 53/110 (48) 11/21 (52)
onditioning regimen
Myeloablative conditioning 48 (100)‡ 101 (84) 19 (79)
TBI-based ablation 77 (64) 17 (71)
Reduced intensity conditioning† — 19 (16) 5 (21)
TG used as part of in conditioning 48 (100) 24 (20) 6 (25) <.001 for BM/PBSCT vs CBT
VHD prophylaxis
CsA ( steroids) plus ATG 48 (100) 3 (3) 4 (17) <.001 for BM/PBSCT vs CBT
CsA plus MTX plus ATG 21 (18) 2 (8)
CsA plus MTX/MMF, without ATG 96 (80) 18 (75)
ollow-up after transplantation, alive/died 17/31 45/75 12/12
ime (mo) to death, median, (range) 2.4 (0.6-23) 3.3 (0.3-54) 1.7 (.6-6.2) .05 for BMT vs CBT and PBSCT
ollow-up (mo) in survivors, median (range) 48 (31-95) 53 (21-95) 38 (16-62) .05 for BMT and CBT vs PBSCT
-Year NRM, % cumulative incidence (95% CI) 48 (23-59) 42 (33-51) 38 (12-51) .3
-year OS, % probability (95% CI) 36 (26-44) 40 (31-49) 38 (24-52) .7
VHD and hematopoietic recovery
GVHD, n (% cumulative incidence)
Grades 2-4/3-4 aGVHD 35 (45)/14 (18) 68 (41)/27 (22) 12 (40)/8 (29) >.1/.1
Extensive cGVHD, n (% cumulative incidence) 6 (9) 23 (16) 4 (15) .1
ematologic recovery,  109/L, median (range)
Day to stable neutrophil engraftment (>0.5)# 22 (13-52) 19 (10-31) 16 (11-23) Detailed below§
Patients with <.5 neutrophils at day 30 4 (8) 1 (1) 0
Day to platelets >20# 67 (10-230) 21 (5-138) 12 (9-38)
Day to monocytes >0.2 27 (13-66) 19 (10-366) 17 (10-23)
Day to lymphocytes >0.2 41 (12-69) 23 (4-399) 17 (7-41)
Day to lymphocytes >0.5 49 (26-147) 36 (8-269) 24 (8-51)
ata are numbers (%) unless otherwise noted. AL indicates acute leukemia; MDS, myelodisplastic syndrome; CML, chronic myeloid leukemia;
PCR-HR, DNA high-resolution HLA testing, to the allele level, by polymerase chain reaction; LR, serologic testing for A, B, or
low-resolution PCR testing; TBI, total body irradiation; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; ATG,
antitymocyte globulin; GVHD, graft-versus-host disease; NRM, nonrelated relapse mortality; NA, not applicable.
Early: Acute leukemia and myelodisplastic syndrome in ﬁrst complete remission after chemotherapy (5% blasts), previously untreated
low-risk MDS, chronic myeloid leukemia in ﬁrst chronic phase. Not early: Other disease status of previously mentioned hemopathies;
multyple myeloma, chronic lymphoid leukemia, non-Hodgkin lymphoma, hodgkin disease, solid tumors.
Included ﬂudarabine-busulfan or ﬂudarabine-melphalan, as previously described.
A homogeneous conditioning regimen was used for all cord blood transplants, with thiotepa, cyclophosphamide, busulfan and ATG, as
previously described [33].
For CBT vs BMT and PBSCT, all cell types recovered faster (P  .01) in the latter groups. For BMT vs PBSCT, all cell types recovered
earlier in the latter (P  .01).
Proportions of patients who did not achieve stable neutrophil engraftment/stable platelet engraftment by stem cell source were 3 (6%)/9 (19%) for CBT recipients and 1 (0.8%)/9 (7%) for BMT-PBSCT recipients, respectively.
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Infections after Unrelated Allogeneic Transplantation in Adults 737ious Diseases Working Party of the European Group
or Blood and Marrow Transplantation (http://www.
bmt.org/5WorkingParties/IDWP/wparties-id6.htm).
hese deﬁnitions included: (1) documented bacterial
nfection of any type and organ site, except bacteremia
y coagulase-negative staphylococci, Micrococcus spp,
nd saprophytic Corynebacterium spp, which were not
ncluded in the present analysis; (2) invasive fungal
nfections (IFIs), which were divided into proved and
robable according to currently accepted criteria [18],
lthough galactomannan-deﬁned probable IA was not
ncluded; (3) CMV infection, deﬁned as the presence
f a single positive antigenemia ( 1 pp65 antigen-
ositive leukocyte among 200 000 cells counted per
lide), CMV viremia on the basis of a positive blood
ulture or shell vial centrifugation culture, or docu-
entation of CMV disease without previous positive
ntigenemia or viremia [19], and CMV disease was
eﬁned as the demonstration of CMV in biopsy or
utopsy specimens from clinically involved visceral
ites by culture and/or histology or if CMV was de-
ected in samples from clinically deﬁned sites of dis-
ase [19]; (4) disseminated varicella-zoster virus infec-
ion, deﬁned as cutaneous involvement of 2 skin
ermatomes or visceral involvement; (5) other severe
iral infections such as human herpesvirus 6 enceph-
litis, Epstein-Barr virus post-transplant lymphopro-
iferative disease, adenovirus disease, and lower respi-
atory tract infection by respiratory viruses were
iagnosed according to criteria of the Infectious Dis-
ases Working Party of the European Group for
lood and Marrow Transplantation [20-22] (detailed
n Table 2); and (6) pneumonia of unknown origin,
eﬁned as any new radiologic lung inﬁltrate in a fe-
rile patient with respiratory symptoms in the absence
f a known pathogen.
Patients were considered to have died from infec-
ion (ie, IRM) if death was attributed to a recent severe
nfection by the primary investigator in each center
nd/or an infection was identiﬁed at autopsy. Patients
ith relapse of their underlying disease before death
ere excluded from this deﬁnition, even if an infec-
ion was the ﬁnal cause of death, whereas those who
ied with clear evidence of a life-threatening infec-
ion were considered to have an IRM. All cases of IRM
s considered by each participating center were veri-
ed by 1 of the study coordinators (R. Martino). How-
ver, a conﬁrmatory autopsy would have been the only
ay of establishing the deﬁnite cause of death. As
resented in Table 3, similar proportions of autopsies
ere done in patients with IRM in all stem cell source
ransplantation groups (21% to 25% of NRMs).
A signiﬁcant number of patients with graft-versus-
ost disease (GVHD) under treatment developed a
linically deﬁned infection before death (pneumonia
n 85% of cases) with no microbiologic ﬁndings and
ften progressing to multiorgan failure despite the use wf multiple antimicrobial agents. Although a probable
r proved infection was not found and an autopsy was
ot granted by the patients’ families, these deaths were
onsidered as IRM of unknown pathogen(s).
The period after transplantation that any event oc-
urred was classiﬁed as early (from days 0 to 30),
ntermediate (days 31 to 100), late (days 101 to
365, ie, 1 year), or very late (day 365 after trans-
lantation).
Disease phase of the underlying disease at transplan-
ation was categorized as early or not early, as deﬁned in
able 1 (see notes). Assessment, grading, and treatment
f acute GVHD (aGVHD) and chronic GVHD
cGVHD) were done using standard methods [23,24].
he stem cell dose infused was categorized separately in
ach transplantation group. The median stem cell dose
er group was calculated, and stem cell doses above the
edian were categorized as high. A high level of stem
ells was deﬁned separately for each stem cell source:
one marrow (4  108/kg total nucleated cells (TNC)
r 4  106/kg CD34 cells), peripheral blood (6 
06/kg CD34 cells), and cord blood (2  107/kg
rozen TNC or 1  105/kg frozen CD34 cells).
he exact dose of cells given was not reported in 10
MT recipients (8%) and 3 PBSCT recipients (12%).
tatistical Analysis
The major endpoint of this study was to com-
are the incidence of IRM in adults who received an
nrelated donor HSCT with CBT versus BMT or
BSCT. Other outcomes analyzed in detail were
RM, CMV infection and disease, IFIs, pneumonia
f unknown origin and overall survival (OS). The
ncidence of these outcomes (except OS) was ana-
yzed with cumulative incidence, with the corre-
ponding competing risk factors for each outcome,
s described in detail elsewhere [25,26]. For OS the
aplan-Meier estimate was used. Although showed
n detail in Table 1, no attempt was made to analyze
n detail risk factors for other important transplan-
ation outcomes (relapse, disease-free survival, he-
atopoietic recovery, aGVHD, cGVHD, and oth-
rs), because they were not the objects of this study.
All bacterial infections and other uncommon se-
ere infections are presented in detail in the tables,
nd univariate analyses were done by pooling together
ll serious bacterial infections (but not multivariate
odels), due to the large number of different patho-
ens involved and the few cases per pathogen. Specif-
cally, rates of serious bacterial infections before day
100 (early-intermediate periods) were analyzed by
nfection density (number of bacterial infections per
000 patient-days).
To avoid erroneously ﬁnding statistically signiﬁ-
ant risk factors, only a prespeciﬁed set of variables
as analyzed in univariate and multivariate testing,
Table 2. Severe Infections in Each Transplantation Group by Period after Transplantation
Early (<Day 30)
Intermediate
(Days 31 to 100)
Late (Days 101 to 365) and
Very Late (after Day 365)
Total Severe Infections
(All Stem Cell Sources,
All Follow-up)
Total
Cases CBT
BMT/
PBSCT
Total
Cases CBT
BMT/
PBSCT
Total
Cases CBT
BMT/
PBSCT
Total
Cases CBT
BMT/
PBSCT
Patients at risk, n* 192 48 144 172 43 129 123 28 95 192 48 144
Patients infected in each period, n 62 26 36 79 17 62 63 21 42 140 41 99
Infectious episodes in each period, n 66 128 104 298
Bacterial infections 32 (17) 15 (31) 17 (12) 23 (13) 3 (7) 19 (15) 26 (21) 9 (32) 17 (21) 72 (38) 31 (64) 77 (53)
Bacteremia† 28 12 (25) 16 (11) 27 2 (5) 25 (19) 21 7 (25) 14 (15) 76 21 (44) 55 (38)
Gram-negative bacteria 19 10 (21) 9 (6) 21 19 59
Escherichia coli 8 6 2 6 — 6 (5) 5 1 4 19
Other enterobacteria 2 1 1 6 — 6 7 2 5 21
Pseudomonas aeruginosa 4 1 3 3 — 3 3 — 3 10
Other GNFGNB 1 1 — 6 2 4 4 2 2 11
Others GNB 4 1 3 — — — — — — 4
Gram-positive bacteria 9 2 (4) 7 (5) 6 2 17
Staphylococcus aureus 4 1 3 1 — 1 1 1 — 6
Enterococcus spp. 1 — 1 2 — 2 1 1 — 4
Viridans group streptococci 3 1 2 — — — — — — 3
Other GP bacteriae 1 — 1 3 — 3 — — — 4
Pneumonia‡ 5 4 (8) 1 (1) 10 1 (2) 9 (7) 8 2 (7) 6 (6) 23 7 (14) 16 (11)
Gram-negative bacteria 4 7 6 17
Escherichia coli — — — — — — 1 — 1 1
Other Enterobacteriaceae — — — 2 — 2 1 — 1 3
Pseudomonus aeruginosa 2 1 1 1 — 1 2 1 1 5
Other GNFGNB* 2 2 — 4 1 3 2 — 2 8
Gram-positive bacteria 1 3 2 6
Staphylococcus aureus 1 1 — 2 — 2 1 1 — 4
Enterococcus spp. — — — — — — — — — —
Viridans group streptococci — — — — — — — — — —
Others GP bacteria — — — 1 — 1 1 — 1 2
Meningitis§ 2 2 1 1 1 — 1 — 1 4 3 1
Other sites involved 1 — — — — 4 — 4 5 — 5
Bacterial infection density 13 10 8 4
Invasive fungal infections (n patients) 9 (5) 5 (10) 4 (3) 12 (7) 5 (12) 9 (7) 15 (11) 1 (4) 14 (15) 38 (19) 12 (23) 25 (17)
Candidemia¶ 6 3 3 6 2 4 — — — 12 (6) 5 (10) 7 (5)
Invasive aspergillosis# 3 2 1 9 4 5 14 1 13 26 (14) 7 (15) 19 (13)
Invasive pulmonary aspergillosis 3 2 1 7 3 4 1 1
Other sites — — — 1 1 — — 5 (1 v late)
Other IFIs** 2 2 2 2
Toxoplasmosis disease (n patients) — — — 4 (2) 2 2 4 (2) 4 (4) —
Viral infections (n patients) 18 (9) 8 (17) 10 (7) 54 (31) 9 (21) 45 (35) 27 (22) 14 (50) 13 (14) 102 (53) 29 (60) 73 (51)
CMV
Infection 11 (6) 7 (15) 4 (3) 52 (30) 9 (21) 43 (33) 12 (10) 4 (17) 8 (8) 75 (39) 20 (42) 55 (38)
Disease 1 — 1 11 (10) 3 (7) 8 (6) 10 (8) 5 (21) 5 (2 v late) 22 (11) 7 (17) 15 (10)
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Table 2. Continued
Early (<Day 30)
Intermediate
(Days 31 to 100)
Late (Days 101 to 365) and
Very Late (after Day 365)
Total Severe Infections
(All Stem Cell Sources,
All Follow-up)
Total
Cases CBT
BMT/
PBSCT
Total
Cases CBT
BMT/
PBSCT
Total
Cases CBT
BMT/
PBSCT
Total
Cases CBT
BMT/
PBSCT
HSV 1/2 3 1 2 2 1 1 7 (6) 1 6 (3 v late) 12 (6) 3 (6) 9 (6)
VZV (>2 dermatomes) 1 — 1 1 — 1 22 (18) 11 (1 v late) 11 (5 v late) 24 (12) 11 (23) 13 (9)
HHV-6 encephalitis 1 — 1 1 — 1 1 1 — 3 1 2
Respiratory virus†† 4 — 4 2 1 1 1 — 1 7 1 6
EBV lymphoproliferative disease — — — 3 1 2 2 1 1 5 2 3
CB indicates cord blood; BM, bone marrow; PB, peripheral blood; GNFGNB, glucose nonfermenting negative gram bacteria; GNB, gram-negative bacillus; GP, gram-positive; CMV, cytomegalovirus;
HSV, herpes simplex virus; VZV, varicella-zoster virus; HHV-6, human herpex virus 6; CRV, community respiratory virus; EBV, Epstein-Barr virus; v late, very late.
*Number of patients alive and without progression or relapse of their underlying malignancy at the start of each period analyzed. Groups of severe infection (bacterial, fungal, viral, and toxoplasmosis)
are expressed as number of patients (percentage of patients at risk), but different subsets refer to infectious episodes that may not be coincident with number of patients, because there were patients
that developed 1 severe infection.
†Bacteremias (number of episodes). Other Enterobacteriaceae include Enterobacter cloacae (4), Proteus mirabilis (3), Serratia liquefaciens (1), Samonella spp. (3), Citrobacter freundi (1). Other GNFNGB:
Acinetobacter spp (3), Stenotrophomonas maltophilia (3), Burkholderia cepacia (1) and Pseudomonas stutzeri (1). Other GNB: Fusobacterium nucleatum (3), Capnocytophaga spp (1). Other GP bacteriae:
Leuconostoc spp (1), Clostridium difﬁcile (1), Bacillus cereus (1), Listeria monocytogenes (1).
‡Pneumonias (number of episodes). Other Enterobacteriaceae include: Klebsiella pneumoniae (1), Salmonella spp. (1), Enterobacter cloacae (1). Other GNFNGB: Acinetobacter spp (5), Stenotrophomonas
maltophilia (5). Other GP bacteriae: Streptococcus pneumoniae (1), Nocardia spp (1).
§Meningitis: Staphylococcus aureus (1, early), S. pneumoniae (1, early), Acinetobacter spp. (1, intermediate), Nocardia spp (1, late).
Rates of serious bacterial infections before day 100 were analyzed by the infection density (number of bacterial infections per 1000 patient-days).
¶Includes C krusei (2), C parapsilosis (4), C glabrata (3), C hemicoal (1), C tropicalis (1), undetermined (2).
#Includes A fumigatus (9), A ﬂavus (5), A terreus (1), A niger (3), A candidus (1). Subgroup nonspeciﬁed in 9 cases.
**Mucormycosis, species not identiﬁed (1), Penicillium marneffei (1), Pneumocystis carinii (1).
††Respiratory syncytial virus (3), inﬂuenza virus A (1), adenovirus (3).
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R. Parody et al.740hen appropriate. All post-transplantation events or
isk factors were entered in univariate and multivariate
odels as time-dependent covariates (Table 4). Cox
roportional hazards regression was used to examine
nivariate and multivariate effects of each variable
nalyzed on the outcomes studied. Because the effect
f the stem cell source group had a time-varying effect
or the incidence of IFIs, especially IA, this outcome
as divided into early and late events at an optimal
ime point as estimated by visual analysis of the cu-
ulative incidence curves (around day 100).
Multivariate analyses included those variables with
P value .1 in previous univariate testing. To ana-
yze the effect of lymphocytopenia, monocytopenia,
nd neutropenia in each period, the counts reported
n day 30 and those reported for patients still at risk
t the beginning of each period were used. To com-
are characteristics of case patients with controls,
ummary statistics, including frequency counts and
able 3. Overall Infectious Mortality and Causes of Death (Frequency
peciﬁed Otherwise)
CBT
(n  48)
eaths, n 31 (65)
00-Day IRM, % cumulative incidence (95% CI) 30 (10-4
-Year IRM, % cumulative incidence (95% CI) 40 (12-5
ostmortem studies done, n (% NRM) 6 (21)
RM* 19 (61)
Bacterial infection, n deaths/n cases (%) 9/31 (29)
Pneumonia 4/7
Meningitis 3/3
Bacteremia  other site(s) 2/21
CMV disease 3/7
Disseminated adenovirus disease —
Respiratory syncitial virus pneumonia —
Invasive fungal infections, n deaths/n cases (%) 7/11 (64)
Invasive aspergillosis 5/7
Disseminated candidiasis 2/5
Toxoplasmosis 1/2
Pneumonia of unknown etiology 5/7
Severe GVHD  CDI  MOF† 10 (32)
eriod after transplantation of IRM (%)
Early (< day 30) 5 (26)§
Intermediate (days 31 to 100) 9 (47)§
Late (days 101 to 365) 4 (21)
Very late (> day 365) 1 (5)
ther causes of NRM 9 (29)
elapse of underlying malignancy‡ 3 (6)
MT indicates bone marrow transplantation; PBSCT, peripheral
infection-related mortality; NRM, nonrelapse mortality; GVHD
multiorgan failure.
Total number of patients who died of IRM in each group. Differen
linked to multiple causes in some of them.
Included number of patients with a clinically deﬁned infection bef
of multiple antimicrobials. However, no pathogens were found
Percentage refers to total number of patients in each group (alive
In the 70 BMT/PBSCT recipients who were known to have an 8/8
in the 26 patients with a known mismatch (8/26, 30%) or CBT
mismatched BMT/PBSCT or CBT).ercentages for categorical variables, and medians and aanges were calculated. Comparisons from 2  2 ta-
les were made by means of chi-square or Fisher exact
tests. The median times until onset of events were
ompared by means Wilcoxon rank-sum test. Cumula-
ive incidence curves up to 3 years after transplantation
ere produced for all events analyzed, because the me-
ian follow-up for survivors exceeded 3 years in all study
ohorts (detailed in Table 1). Quantitative variables were
e-entered as qualitative or binary variables only if at
east a trend for statistical signiﬁcance (P  .08) was
ound. Tests of signiﬁcance were 2-sided, with a signif-
cance level of P .05. However, because the number of
tatistical tests being carried out was high for the sample
izes, ﬁnal multivariate P values between .1 and .02 were
onsidered as trends, whereas those .01 were consid-
red as truly statistically signiﬁcant.
Before comparing CBT with the other stem cell
ources, we analyzed the effect of BMT versus PB-
CT on all outcomes. There were no differences in
spect to Total Patients Who Died in Parentheses, Unless
BMT
(n  120)
PBSCT
(n  24) P
75 (62) 12 (50)
28 (19-37) 22 (9-25) .2
42 (33-51) 38 (12-51) .5
15 (25) 2 (22) .8
42 (56) 8 (67)
9/69 (13) 4/8 (50)
8/14 2/2
1/1 0 >.1 for all causes of IRM
0/54 2/6
7/12 2/3
— 1/1
1/2 —
19/23 (83) 1/2 (50)
16/17 1/2
3/7 0
0 2/2
18/28 4/6
24 (32) 3 (25)
.2
3 (7)§ 2 (25)§
16 (38)§ 4 (50)§
19 (45) 2 (25)
4 (9) —
17 (23) 1 (4)
15 (12) 3 (12)
tem cell transplantation; CBT, cord blood transplantation; IRM,
-versus-host disease; CDI, clinically documented infection; MOF,
gies are not necessarily coincident with patients because death was
th associated with severe GVHD, leading to MOF despite the use
time of autopsy, if performed.
ad).
atch, IRM before day 100 was only 5% (4/70), much lower than
nts (P  .01 for the comparison of fully matched BMT/PBSCT vswith Re
0)
8)
blood s
, graft
t etiolo
ore dea
at the
and de
allele m
recipieny outcome between these 2 latter groups, so these
g
a
d
R
H
G
1
1
c
P
o
P
l
S
s
i
q
o
r
.
T
i
C
d
l
t
r
e
e
o
i
o
a
i
p
t
s
I
o
T
C
*
†
‡
§
k facto
Infections after Unrelated Allogeneic Transplantation in Adults 741roups were combined for univariate and multivariate
nalyses, although they are tabulated separately in the
escriptive Tables 1, 2, 3 and 5.
ESULTS
ematologic Recovery and GVHD
Detailed characteristics of hematologic recovery and
VHD by stem cell transplant source are listed in Table
. Median times to reach a neutrophil count of .5 
09/L, a monocyte count of .2  109/L, and a lympho-
yte count of .2  109/L were shorter in the BMT/
BSCT groups. There was a trend for a lower incidence
f severe aGVHD in the CBT group (18% versus 24%,
 .1). A similar trend was found in the 3-year cumu-
ative incidence of extensive cGVHD (P  .1).
evere Infections
A detailed description of all severe infections is pre-
ented in Table 2. Two hundred ninety-eight severe
nfections were documented in 140 of 192 patients. Fre-
uencies of severe infections at 3-year follow-up were 41
f 48 (85%), 83 of 120 (69%), and 16 of 24 (67%) in
able 4. Variables Tested in Univariate and Multivariate Models (if A
Related to transplant
Graft type: bone marrow/peripheral blood stem cells vs cord b
Conditioning regimen: reduced intensity vs conventional myelo
Year of transplant: 1997-2000 vs 2001-2004
Hematopoietic stem cell dose (analyzed only for each stem ce
Level of HLA matching:
A and B antigens by serology or low-resolution PCR and DR
A, B, DRB1, and DQB1 by high-resolution allele-specific PCR
recipients)
Use of antithymocyte globulin in the conditioning regimen
Related to patient and disease
Patient age
Gender and sex match: male patient to female donor vs other
Second transplant, after failure of prior autologous hematopoi
Disease status at transplantation advanced vs early†
Pretransplant CMV risk group: patient positive/donor negative
Post-transplantation variables‡
Use of steroids at >0.5 mg/kg for >2 wk: yes vs no§
Use of ATG for treatment of GVHD§
Severe neutropenia (<.2  109/L) at days 30, 90, 180, and
Severe lymphocytopenia (<.2  109/L) at days 30, 90, 180
Monocytopenia (<.2  109/L) at days 30, 90, 180, and 3
Severe (grade 3-4) aGVHD: yes vs no‡
Chronic GVHD: no vs limited vs extensive
ontinuous variables were ﬁrst analyzed and then reanalyzed as qu
Reduced intensity conditioning regimens were used only in BMT a
of CBT with BMT/PBSCT groups, but only in the outcome a
Second-transplant and advanced disease status were strongly associ
that showed P .01 and had the highest hazard ratio in univariate t
as risk factors in univariate analysis.
All of these variables were analyzed as time-dependent covariates.
Use of high-dose steroids after transplantation and ATG were str
severe (grade 3-4) aGVHD; thus, only the latter was included i
value .01 in all outcomes for which they were identiﬁed as risecipients of CBT, BMT, and PBSCT, respectively (P o009 for CBT group versus BMT/PBSCT group).
here was a trend for a higher incidence of any severe
nfection during the early period (before day30) in the
BT group (54% versus 25%, P  .03), whereas inci-
ences were similar between groups in the intermediate,
ate, and very late periods (30%, 12%, and 15%, respec-
ively, for CBT recipients and 35%, 20%, and 19%,
espectively, for BMT/PBSCT recipients).
Fifty-six patients (29%) had 2 severe infectious
pisodes from different pathogens, without differ-
nces between groups. In the early-intermediate peri-
ds after transplantation (before day  100), bacterial
nfections accounted for most severe infections (55%
f episodes versus 14% IFIs and 32% viral infections)
s opposed to the late/very late periods, when viral
nfections represented 55% of severe infectious com-
lications (P  .01). These differences in pathogen
ypes between periods were similar among stem cell
ource transplantation groups (Table 2).
nfection-Related Mortality
As presented in Table 3, IRM was the primary
r secondary cause of death (with or without an-
le)
ansplantation
n*
e separately)
igh-resolution allele-specific PCR
zed only in bone marrow/peripheral blood stem cell transplant
m cell transplantation: yes vs no†
er combinations
360
e variables if a statistical trend was found for any outcome.
CT recipients; hence, this variable was not used in the comparison
of these latter transplantation groups.
r showed strong collinearity) with each other; thus, only the variable
was included in multivariate models if both variables were identiﬁed
ssociated (or showed strong collinearity) with the development of
ivariate models, because it showed the highest hazard ratio with P
rs in univariate analysis.pplicab
lood tr
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R. Parody et al.742able 5. Summary of Results of Multivariate Analyses for IRM, CMV Infection, and NRM*
Overall Analysis CBT (n  48) BMTPBSCT (n  144
Multivariate P HR (95% CI) Multivariate P HR (95% CI) Multivariate P HR (95%
RM (n  72)*
Cord blood transplant as stem cell source .5 —
Neutropenia (<0.2109/1) on day 30† <.01 3.9 (2.3-4.8) .05 NR .04 NR
Monocytopenia on day 30 or at the
start of each period† <.001 4.7 (1.9-16) <.01 2.6 (1.2-1
Acute GVHD grades 3-4† .01 2.4 (1.2-4.7) <.001 3.5 (2-4.2
Low stem cell dose infused‡ <.01 2.9 (1.2-3) .05 NR .08 NR
Any HLA mismatch .06§ NR .7 NR .05
MV infection (n  75)
Any HLA mismatch <.05§ NR .5 .08
Acute GVHD grades 3-4† <.001 2.7 (1.7-4.4) <.001 3.6 (2-6)
Patient CMV immunoglobulin G positive <.001 4.3 (2.3-oo) .02 2.5 (1.6-oo) <.0001 4.8 (2.2-o
Cord blood transplant as stem cell source .2 — — —
Extensive chronic GVHD† .05 NR
RM
Cord blood transplant as stem cell source .4 —
Second HSCT .03 NR <.01 2.2 (1.2-4
Monocytopenia on day 30† <.001 4.5 (1.4-18) <.001 11 (6.5-2
Acute GVHD grades 3-4† .01 2.1 (1.2-2.6) .8# .01 1.9 (1.2-3
Any HLA mismatch .07§ NR .01 2.5 (1.7-3
Neutropenia on day 30† .05 NR
Low stem cell dose‡ <.01 2.2 (1.6-3.1) .02 4.1 (2.2-7.1)
FIs (n  38) Univariate Univariate
Early-intermediate periods (before day 
100) (IA  14/IC  12) n  6 n  19
Cord blood transplant as stem cell
source .3 —
Acute GVHD grades 3-4† .001/NS 4.1 (1.9-15) .01 — .001 —
Neutropenia on day 30† .01/0.03 NR/NR .01 — .01 —
Conventional conditioning Not applicable — Not applicable .04 —
CMV disease† .07/NS NR/— .04 —
Use of ATG for treating aGVHD† .02/— NR/— <.01 —
Monocytopenia on day 30† .05/NS — .05 — — —
Late-very late periods (> day 100) (All
IA  12) No cases n  12
BM-PBSC as stem cell source .05 —
Acute GVHD grades 2-4† .001 6 (2.5-9.5) .001
CMV disease† .09 NR .05
Lymphocytopenia on day 90 or at the
start of each period† .08 NR .02
Extensive chronic GVHD† .01 3 (1.3-142) <.001
Monocytopenia on days 90 and 180† — — .04
Use of ATG for treating aGVHD† — — <.01
MV disease (n  22) Univariate Univariate
Cord blood transplant as stem cell source .3 —
Prior CMV infection .04 NR <.01 .01
Extensive chronic GVHD† <.01 9 (2.4-33) <.001 <.01
Patient CMV IgG positive <.001 14 (10-oo) .001
Acute GVHD grades 3-4† — — .01
Conventional conditioning Not applicable — .04
For invasive fungal infections and CMV disease, multivariate analysis was done for all 192 patients, but only univariate results for each
transplantation group are shown, due to the few events per group. The stem cell transplant group (CBT vs BMT/PBSCT) was introduced
in all overall multivariate analysis, despite being nonsigniﬁcant in univariate testing, because it was the main objective of this study.
MT indicates bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; CBT, cord blood transplantation; GVHD,
graft-versus-host disease; CMV, cytomegalovirus; IFI, invasive fungal infection; HSCT, hematopoietic stem cell transplantation; NR, not
reported if P  .01, as described in Statistical Analysis; HR, hazard ration; CI, conﬁdence interval. HRs and 95% CIs are shown for all
signiﬁcant variables.
onocytopenia on day 30 or at the start of each period refers to the presence of monocytopenia at the start of each period after
transplantation (intermediate, late, and very late).
Other variables included in the multivariate analysis for IRM in all 192 patients were advanced disease status (univariate P  .01) and chronic
extensive GVHD (univariate P  .01). In the BMT-PBSCT group, the main variable that was nonsigniﬁcant in the multivariate analysis
was chronic extensive GVHD (univariate P  .02). In the CBT group, nonsigniﬁcant variables in multivariate analysis were advanced
disease status (univariate P  .06) and chronic extensive GVHD (univariate P  .02).
Factors entered into the model as time-dependent covariates.
Low stem cell dose is deﬁned in text.
Refers to any HLA mismatches identiﬁed by serology (antigen mismatch) or by low-resolution PCR-based mismatches in HLA-A and -B and
DRB1 by high-resolution PCR allele-level testing (4-5/6 vs 6/6).
Refers to any HLA mismatches identiﬁed by serology (antigen mismatch) or by high-resolution allele-level PCR testing in HLA-A, -B, -C,and DRB1 (7/8 vs 8/8), as detailed in text.
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Infections after Unrelated Allogeneic Transplantation in Adults 74355% of all deaths in all stem cell source transplan-
ation groups. The 100-day and 3-year incidences of
RM did not differ between groups (Table 3 and
igure 1). Speciﬁc causes of death are presented in
etail in Table 3, but due to the few cases for most
peciﬁc pathogens, no statistical comparisons can be
one between transplantation groups, although
here appeared to be no large differences between
hem. The proportion of IRMs that occurred during
he ﬁrst 100 days after CBT (14 of 19, 73%) was
igher than in the BMT/PBSCT groups (25 of 50,
0%; P  .02).
Table 5 presents multivariate analyses of risk fac-
ors for IRM in all 192 patients and in each transplan-
ation group studied. An interesting ﬁnding is that
eutropenia on day 30 and monocytopenia on day
30 or at the last period analyzed had the strongest
egative effect on IRM (highest hazard ratio) in mul-
ivariate analyses of all 192 patients. The negative
ffect of monocytopenia was also found in BMT/
BSCT recipients, although neutropenia on day 30
howed a trend in both transplant types. Of note, the
resence of any HLA mismatch in BMT/PBSCT re-
ipients showed a trend for a higher IRM (and clearly
ncreased NRM and decreased OS, as described below
n Table 5). In contrast, the presence of 0 to 1 mis-
atch or 2 mismatches in A, B, and DRB1 in CBT
ecipients had no effect on IRM or any other trans-
Months after transplantation 
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igure 1. Three-year cumulative incidence of IRM by stem cell
ransplantation group.lantation outcome.MV Infection and Disease
Seventy-ﬁve patients (39% overall, 52% in CMV-
eropositive patients) presented CMV infection and
2 with CMV disease (detailed in Tables 2 and 5). The
-year cumulative incidences of CMV infection and
isease were similar in all transplantation groups (29%
n CBT versus 30% in BMT/PBSCT recipients and
.2% versus 6%, respectively). Of note, the propor-
ion of CMV disease occurring after day 100 was
igh in both transplantation groups (4 of 7, 57%, in
BT group and 6 of 15, 40%, in BMT/PBSCT
roup). Two additional cases of late CMV disease
ccurred in 2 patients with previous CMV disease
efore day 100.
However, CMV infection showed a trend for ear-
ier onset in CBT recipients. Median days after HSCT
f onset of CMV infection was 52 (range, 9-244) in
BT recipients and 82 (range, 35-859) in BMT/
BSCT recipients (P .05), and proportions of CMV
nfections that occurred before day 30 was higher in
he CBT group (35% versus 7%, respectively; P 
006). Quantitative CMV antigenemia was available in
0 of 75 patients with CMV infection. To determine
hether there was any correlation between the mag-
itude of CMV antigenemia and subsequent develop-
ent of CMV disease, we compared the maximum
umber of positive cells in patients with and without
MV disease, without any apparent correlation (data
ot shown).
In univariate and multivariate analyses, patient
MV seropositivity was the major risk factor for
MV infection and disease, and previous CMV infec-
ion treated preemptively with ganciclovir and/or fos-
arnet increased the risk of developing disease (Ta-
le 5). More speciﬁcally, all 10 cases of a ﬁrst episode
f CMV disease that occurred after day 100 had
een successfully treated preemptively for CMV in-
ection before day 100, and 2 additional patients,
ho had developed an episode of CMV disease before
ay 100 and had been successfully treated, had a
econd episode of CMV disease after day 100.
ransplantation group had no effect on risk of CMV
nfection and disease. Nevertheless, when analyzing
nly seropositive patients for CMV before HSCT,
here was a trend for a higher risk of CMV disease in
BT recipients. Other variables included in the mul-
ivariate analysis for CMV infection in all 192 patients
ere use of antithymocyte globulin for treating
GVHD (univariate P  .05) and lymphocytopenia
.2  108/L on days 30 and/or 90, univariate
 .03). In the BMT/PBSCT and CBT groups, the
nly variable that was nonsigniﬁcant in multivariate
nalysis was lymphocytopenia (.2  108/L on days
30 and/or 90, univariate P  .04 and .01, respec-
ively).
Because extensive cGVHD was the strongest risk
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R. Parody et al.744actor for CMV disease in both transplantation groups
n univariate analysis, we compared the incidence of
ate CMV disease by transplantation group and exten-
ive cGVHD. For this comparison, a landmark anal-
sis was done, including only seropositive patients
ho were evaluable for cGVHD (alive and well on day
100; CBT, n  19; BMT/PBSCT, n  70), and
alculated the incidence of CMV disease in each
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A: No extensive cGVHD 
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igure 2. Landmark analysis (including only patients alive and well
n day 100 after transplantation) of 3-year cumulative incidence
f CMV disease in patients seropositive for CMV before transplan-
ation by (A) not developing or (B) developing extensive cGVHD
fter day 100, split by stem cell source transplantation group.roup. As seen in Figure 2, there was a trend for a higher rate of CMV disease after day 100 in both
ubgroups of CBT recipients (2 of 5, 40%, with ex-
ensive cGVHD and 3 of 14, 21%, without extensive
GVHD) compared with BMT/PBSCT recipients (4
f 21, 19%, and 3 of 49, 6%, respectively). Due to the
mall numbers of patients and events per subgroup, no
tatistical comparison was done.
ecurrence of CMV Infection
Sixteen patients (21% of patients with CMV in-
ection) had recurrent CMV infections (11 had 2 ep-
sodes and 4 had 2 episodes). Risk factors for recur-
ent CMV infections could not be analyzed due to the
mall samples, but the rate was similar in all transplan-
ation groups and recurrent infection apparently did
ot increase the risk of CMV disease.
ther Severe Viral Infections
Severe infections by all other viruses were diag-
osed less commonly than CMV (Table 2). Thirty-
ine cases of nonlocalized infections by other herpes
iruses occurred, and varicella-zoster virus infections
ere the most pathogens in all study groups (23% of
BT recipients and 10% of BMT/PBSCT recipients).
ost varicella-zoster virus infections occurred after
ay 100 (11 of 11, 100%, and 11 of 13, 87%, re-
pectively).
Less common non-CMV viral infections included
pstein-Barr virus lymphoproliferative disease and
ommunity respiratory virus infections in 3% and 4%
f patients, respectively. However, only 2 patients
ied from non-CMV viral infections (disseminated
denovirus disease and respiratory syncytial virus
neumonitis), although both patients also had CMV
isease and IA.
Eleven patients (6.5%) developed hemorrhagic
ystitis with the presence of Polyoma virus in urine.
owever, because this observation did not sufﬁce to
ttribute the cystitis to this virus, we did not include
hese cases as severe viral infections. All episodes of
ystitis resolved with supportive measures.
acterial Infections and Pneumonia
f Unknown Origin
Seventy-two patients (37%) presented 108 severe
acterial infections after transplantation. All bacterial
pecies found are shown by period and type of stem
ell source in Table 2. Gram-negative bacilli infections
redominated in all periods and stem cell transplantation
roups, but this predominance of gram-negative ba-
illi was due to exclusion of coagulase-negative staph-
lococci from analysis, which account for most infec-
ions in all recent large studies [2,4,9,29].
Although there were no relevant differences in any
peciﬁc bacterial pathogens found, CBT recipients
ad a higher rate of any serious bacterial infection
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Infections after Unrelated Allogeneic Transplantation in Adults 745efore day100. Thus, the bacterial infection density
efore day 100 in CBT recipients was higher than
hat in BMT/PBSCT recipients (21 infections per
000 patient-days in CBT group versus 14 in BMT/
BSCT group, respectively; P  .04). Twenty-two
atients died from a bacterial infection, as shown in
able 5. The highest mortality was seen for bacterial
neumonias (14 of 23 episodes, 61%) and meningitis
4 of 4 episodes).
Forty-one patients (21%) had 1 episode of clin-
cally deﬁned pulmonary infection but no pathogen
as identiﬁed (pneumonia of unknown origin or
UO), with similar rates in all transplantation groups
nd similar attributable mortality (5 of 7 in CBT
roup and 22 of 34 in BMT/PBSCT group, P  .8).
t day 100 and at 3 years the cumulative inci-
ences of PUO were 7% and 15%, respectively, in
BT recipients and 10% and 17% in BMT/PBSCT
ecipients (P  .3). In the CBT group, 3 of 7 cases of
UO (43%) occurred before day 100 and 4 of 7
57%) occurred 1 year after transplantation; in the
MT/PBSCT group, the time distributions were 21
f 34 (62%) and 12 of 34 (35%), respectively (P  .7).
n univariate analysis, the only risk factors that showed
trend for PUO were advanced disease status (P 
07), mismatched sex (P  .06), and the presence of
ymphocytopenia on day 30 (P  .03).
nvasive Fungal Infections
Thirty-eight patients (19%) developed 40 epi-
odes of a probable or proved IFI. Twenty-six epi-
odes (71%) were IA, and 12 (29%) were caused by
on-Candida albicans (see Table 2 for details). There
as 1 episode of P jiroveci pneumonia, 1 of Penicillium
arneffei fungemia, and 1 of histologically proved
ucormycosis. Death from an IFI did not differ be-
ween transplantation groups (22 of 26 cases of IA,
5%, and 5 of 12 cases of invasive candidiasis, 42%).
The CBT group showed a statistically signiﬁcant
rend (P  .01) in developing a higher proportion of
FIs before day 100 (12 of 12 IFIs) compared with
he other group (11 of 25, 40%). However, the 3-year
umulative incidence of developing an IFI in all 192
atients was 12% (95% conﬁdence interval [CI], 6 to
8) and did not differ between transplantation groups.
ncidences of IA and candidiasis were 10% and 2%,
espectively. Median times to onset were 148 days
range, 14-622) for IA and day 48 (range, 4-122) for
andidiasis.
To estimate possible risk factors for IA, only uni-
ariate analyses are reliable, and the results are shown
n detail in Table 5. Before day 100, development of
evere (grades 3 to 4) aGVHD and delayed neutrophil
ecovery increased the risk of IA in CBT and BMT/
BSCT recipients. Risk factors for late cases of IA
after day  100) included aGVHD grades 2 to 4, (xtensive cGVHD, and use of antithymocyte globulin
or treating severe GVHD. Of note, stem cell source
ad no effect in early IA, although a trend for a higher
isk in the BMT/PBSCT group was found (12 of 95
valuable patients, 13%, versus 0 of 28 CBT recipi-
nts, respectively; P .05). No risk factors were found
or the 12 cases of Candida infection, except for a trend
or neutropenia on day 30. Interestingly, all cases
ere due to non–Candida albicans species.
ther Severe Infections
nd Simultaneous Infections
Numerous uncommon opportunistic infections
ere found, as detailed in Table 2. Of note, toxoplas-
osis disease was diagnosed before death in 4 cases (2
BT and 2 PBSCT recipients), but the actual fre-
uency in patients at risk (patients seropositive for
mmunoglobulin G for Toxoplasma gondii before trans-
lantation) was 4 of 77 (5%), with 3 patients dying
rom disseminated toxoplasmosis.
Twenty-one patients (11%) had 1 episode of
imultaneous severe infections, which had a high at-
ributable mortality (76%). The most common asso-
iations were fungal and viral infections. CMV pneu-
onia preceded or occurred simultaneously with
robable or proved aspergillosis in 7 cases (27% of
A), and 2 cases of IA coexisted with an Epstein-Barr
irus lymphoproliferative disease and respiratory syn-
ytial virus pneumonia, respectively.
RM and OS
NRM occurred in 20 (41%) and 76 (52%) patients
n the CBT and BMT/PBSCT groups, respectively, at
edians of 149 days (range, 16-573) and 189 days
range, 69-671) after transplantation, respectively.
he 100-day and 3-year cumulative incidences of
RM in the CBT versus BMT/PBSCT group were
5% (95% CI, 7 to 39) versus 12% (95% CI, 7 to 25)
nd 48% (95% CI, 13 to 99) versus 41% (95% CI, 29
o 49), respectively (P  .2 for both comparisons).
he speciﬁc causes of NRM and death and univariate
nd multivariate analyses of risk factors for NRM are
resented in Table 5.
Thirty-nine percent of all patients were alive at
nal follow-up, with a median follow-up of 50 months
range, 24-95). OS at 3 years was 36% in the CBT
roup and 39% in the BMT/PBSCT group (P  .7).
n multivariate analysis by stem cell source group, vari-
bles that decreased 3-year OS in the BMT/PBSCT
roup were (1) a previously failed autologous HSCT
P  .004), (2) monocytopenia on day 30 (P  .01),
3) grade 3/4 aGVHD (P  .01), (4) not developing
imited cGVHD (P  .0001), and (5) any HLA
ismatch by high-resolution typing (P  .01). In
he CBT group, deleterious variables for OS were
1) age35 years (P .01), (2) advanced disease status
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R. Parody et al.746t transplantation (P  .02), (3) neutropenia on day
30 (P .02), and (4) low nucleated cell dose infusion
P  .01).
ISCUSSION
Most single-center and multicenter or registry-
ased studies have shown that adult recipients of a
UD HSCT have a high risk of developing severe
nfections, although most studies to date are ham-
ered by the description of selected homogeneous
atient cohorts, by the lack of speciﬁc data on the true
LA mismatches between donor and recipients, and
y a lack of comparison of CBT as a source of stem
ells [1,2,10,27-30]. Clinicians who perform VUD
ransplantation in adults are aware that severe infec-
ions are very common, generate important morbid-
ty, and require costly and complex diagnostic and
herapeutic interventions. Despite the obvious limita-
ions of the present multicenter and retrospective
tudy, we aimed at describing the exact numbers and
isk factors for severe infections in all VUD transplan-
ations performed during a recent period, without
atient selection, in an effort to describe the problems
aced in real clinical practice, However, the statistical
nalysis was rigorously designed (detailed in Statistical
nalysis), so comparative analyses of outcomes were
ore reliable; nevertheless, undetected biases can lead
o incorrect observations in any retrospective study.
Our ﬁndings on the frequencies and cumulative
ncidences of major life-threatening infections are in
ine with previous studies in VUD HSCT in adults,
ainly IFIs (13% cumulative incidence), CMV infec-
ion and disease, and IRM [4,5,10,11]. With respect to
he 2 former severe infections, we found that many
ases occurred late after transplantation (after day
100), as reported recently [4,5,10,30]. Thus, 54% of
FIs and 45% of CMV disease occurred after day
100, with similar proportions in all transplantation
roups. In addition, 30% of IRM occurred after day
100. Although the deﬁnitions may vary somewhat,
RM was responsible for50% of all cases of NRM in
ther studies of VUD HSCT in adults [13-15,31-33].
Because CBT has been investigated as a source of
lternative donor stem cell source for VUD transplan-
ation in adults only recently, there is little detailed
nformation on the infectious complications after
BT, especially when compared with other VUD
tem cell sources. Nevertheless, recently published
nalyses have indicated that survival appears to be
imilar to BMT from VUD [12-14]. The patterns and
ypes of severe infections seen in CBT in adults are
mportant to clinicians, because the feasibility of CBT
n adults was questioned by many physicians only a
ew years ago, due to the anticipated high risk of graft
ailure, delayed hematopoietic recovery because of the Imall number of stem cells infused, and lack of im-
une reconstitution [10,12,13,15,29,34].
Our study shows that CBT recipients have a
igher incidence of severe infections, especially bac-
erial infections, in the ﬁrst 100 days after transplan-
ation. In addition, the proportions of CMV infec-
ions, IFIs, and IRMs that occurred before day 100
ere higher in CBT recipients than in BMT/PBSCT
ecipients. However, after day 100, CBT recipients
ppeared to have a lower risk of most severe infec-
ions. Most importantly, the 100-day and 3-year inci-
ences of IRM and NRM were not different between
roups. In any type of allogeneic HSCT, the inci-
ence and risk factors for bacterial, fungal, and viral
nfections are correlated with the kinetics of myeloid
nd immune reconstitution [29,30,35]. Early infec-
ions are mainly attributed to neutropenia and to the
amage of mucosal barriers, and the higher risk of
arly infections may reﬂect the delay in myeloid re-
overy in CBT with respect to BMT/PBSCT recipi-
nts [11,16,17]. Several ongoing studies are attempt-
ng to fasten hematopoietic recovery and thereby
ecrease infection in the early period after CBT, such
s coinfusion of a third-party, haploidentical, fully
-cell–depleted PBSCT from a haploidentical rela-
ive [36], and a comparison of early infections with and
ithout such strategies would be of great interest.
After engraftment, cell-mediated immunity is of
tmost importance, and infections are increased in
ase of GVHD and its immunosuppressive treatment
37,38]. Thus, we made an effort to analyze the effect
n postengraftment infections of neutrophil, lympho-
yte, and monocyte counts as time-dependent covari-
tes. An interesting observation was the strong effect
f monocytopenia in multivariate analyses on NRM
nd IRM (especially in the BMT/PBSCT group) and
n IFIs. In support of our ﬁndings, a study by Storek
t al [39] in Seattle found that a low monocyte count
n day 80 was an independent risk factor for the
evelopment of any severe infection and severe viral
nd fungal infections after day 100 in 103 BMT
ecipients. In addition, a recent abstract from a mul-
icenter 1-year study in France found that monocyto-
enia was an independent risk factor for a poor out-
ome of IA among 51 HSCT recipients [40]. The
xact reason for these observations is unclear, and the
onocyte count could simply be a surrogate marker of
he truly relevant biologic mechanism of its protective
ffect or could have a direct role on nonspeciﬁc im-
une defense mechanisms [39]. As expected, we found
hat severe GVHD increased the risk of most severe
nfections before and after day 100. The lower risk
f severe cGVHD seen in CBT [12,13] may explain
he trend for lower risk of late infections, especially
FIs, seen in our study.
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nd overall mortality after HLA-matched VUD BMT
ut similar outcomes between CBT and HLA-mis-
atched VUD BMT. Our results are in line with this
tudy, because we found a lower IRM in 8of 8 allele-
atched BMT/PBSCT recipients with respect to mis-
atched BMT/PBSCT and CBT recipients (P .01),
hereas the level of HLA matching had no effect on
ny outcome in CBT recipients [12,15]. In addition, a
igh cell dose was a protective variable for IRM and
RM in CBT recipients, thus emphasizing the need
f using the cellularity of the cord blood unit as the
ain variable when selecting a unit for transplantation
15]. However, our results must not be overinter-
reted, because the small number of cases at each level
f mismatching gives the study low statistical power to
etect an effect of the number of mismatches. More-
ver, the deﬁnition of an HLA match in this study
ncluded only 6 HLA loci and low-resolution typing
or class I antigens in CBT recipients, whereas high-
esolution matching was available for a large propor-
ion of BMT/PBSCT recipients. This handicap was
xpected, because, in accord with current recommen-
ations, cord blood units were typed with low resolu-
ion for HLA-A and HLA-B during the study period,
ut BMT/PBSCT donors were usually selected with
he use of criteria that included high-resolution typing
or 8 or 10 HLA antigens [41-43]. However, most
xperts agree that, when large numbers of CBT have
een typed by high-resolution HLA typing, mis-
atches that lead to worse outcomes, including IRM,
ay be identiﬁed [14,41,44].
In conclusion, with a median follow-up of 3
ears, unrelated donor CBT in adults was associated
ith similar risks of IRM and all major severe infec-
ions with respect to VUD BMT/PBSCT. These re-
ults highlight that, with an appropriate selection of
ord blood units, CBT should continue to be devel-
ped as a source of alternative donor HSCT in pa-
ients who lack an allele-level matched adult donor.
he true relevance of monocytopenia as an indepen-
ent risk factor for some severe infections merits fur-
her studies.
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